Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction
Recommendation: OUTPERFORM
Target Price: EUR4.10
Current Price: EUR2.80 (COB on 2^nd August 2018)

KEY TAKEAWAY

Mauna Kea reported H1/2018 sales of EUR2.7m (-18% YoY) slightly below our expectations, mainly due to delays in revenue recognition from new Cellvizio systems installed under the new consignment business model in the US and a 40% decline in sales in EMEA as a result of increased focus on the core clinical business in the US. Importantly, the company reported strong installed base growth, with the number of new consignment systems installed in H1/2018 (16) already exceeding the number of systems installed in FY2017 (13). As a result, we are revising our sales forecasts for FY2018E and FY2019E. Our estimates for out-year remain broadly unchanged as we continue to believe that Mauna Kea is well-positioned to enter a period of accelerated growth, driven largely by its new pay-per-use business model and continuous improvements in reimbursement for procedures involving Cellvizio. We reiterate both our OUTPERFORM recommendation and EUR4.10 target price.

Q2 results reflect increasing momentum in consignment sales

Sales of EUR1.67m in Q2/2018 were in line with sales of EUR1.69m in Q2/2017 (-1% YoY), but 60% above Q1/2018 sales, suggesting that the company may have reached a turning point as the new consignment model in the US is gaining traction and sales efforts are starting to yield results. This is also reflected in the 4.5-fold increase in new consignment systems placed in Q2/2018 vs. Q2/2017. Consumables sales in Q2/2018 were up 33% vs. Q2/2017, mainly driven by a 60% increase in the US.

Adjusting 2018E - 2019E sales, 2020E and beyond broadly unchanged

In light of reported Q2 sales, we are lowering our FY2018E sales estimate from EUR9.4m to EUR8.3m and FY2019 from EUR11.7m to EUR11.1m to account for delays in the monetisation associated with the consignment business model, as well as to reflect the increased emphasis on the US and Chinese markets compared with EMEA. Due to the lag associated with the new business model, we anticipate revenues on the back of the growth in the Cellvizio installed base in H1/2018 to be realised in H2/2018, and the strong sales efforts and new commercial strategy to start to pay off. This assumes H2/2018E sales of EUR5.6m.

Target price of EUR4.10 suggests 43% upside to current levels

We maintain and reiterate our target price of EUR4.10 per share, which is based on an EV/Sales multiple approach using our EUR25.1m revenue estimate for 2022E, a multiple of 4.0x, a discount rate of 11% and a probability rate of 75%. Our positive stance on Mauna Kea is based on (1) continued improvement in reimbursement structures, (2) growing momentum for sales in key target markets such as the US and APAC, and (3) an expansion of the list of applicable medical specialities. Furthermore, the abundance of complementary technology in targeted therapeutic areas offers upside potential through strategic partnerships. We reiterate our OUTPERFORM recommendation.

Kind regards,

Martin Brunninger | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | martin.brunninger@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

Click here to see our privacy policy.

GPSL has a formal client relationship with Mauna Kea Technologies SA.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.

If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=3fd7a0da-d112-4828-8222-fd1dc61e9a17&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.